The Novel Selective Pan-TRK Inhibitor ONO-7579 Exhibits Antitumor Efficacy Against Human Gallbladder Cancer In Vitro.
Anticancer Res
; 38(4): 1979-1986, 2018 04.
Article
em En
| MEDLINE
| ID: mdl-29599313
ABSTRACT
We previously reported that brain-derived neurotrophic factor (BDNF)/neurotrophic receptor tyrosine kinase 2 (NTRK2/TRKB) signaling contributes to induction of malignant phenotype of gallbladder cancer (GBC). Recently, pan-TRK inhibitors have been evaluated and their dramatic clinical activity is being shown for a variety of cancer types harboring an NTRK rearrangement in phase I trials. ONO-7579 is an oral pan-TRK inhibitor currently under investigation in phase I/II clinical trial for TRK-rearranged solid tumors. In this study, we evaluated the anticancer effect of ONO-7579 using GBC cells with or without KRAS mutant, NOZ, TYGBK-1. Our study showed that ONO-7579 had a suppressive effect on GBC proliferation in TYGBK-1, and on invasive potential and vascular endothelial growth factor expression in TYGBK-1 and NOZ. Our data indicated that ONO-7579 could be a promising treatment option for patients with GBC.
Palavras-chave
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Compostos Orgânicos
/
Glicoproteínas de Membrana
/
Receptor trkB
/
Inibidores de Proteínas Quinases
/
Neoplasias da Vesícula Biliar
Limite:
Humans
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article